Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial.

12 major claims checked against the paper's own evidence: all adequately supported.

Recomputed 2 tests: 2 consistent, 0 inconsistent, 2 via agent-written checks.

2 integrity concerns flagged (0 high).

6 copyedit issues flagged: mostly consistency, clarity, punctuation.

Checked 50 references: 49 verified — 1 not checked.

2 data/code links checked; 2 live.

The manuscript is ready to submit after correcting two small internal inconsistencies (denominator discrepancy in Results vs Table 2; sample size typo 1,424 vs 1,428) and adding a code availability statement. These are minor fixes; no reformulation of the science is needed. The methodological rigor is strong and the transparency is high.

1. 1.
   HIGHreporting

   In the Results section (Efficacy outcomes), reconcile the denominators: the text states 130/610 and 126/623 participants, but Table 2 shows total randomized n=611 and n=624. Explain why 1 participant per group is excluded from the denominator (e.g., missing primary outcome data, withdrawn consent) and add a footnote or sentence clarifying.

   This internal contradiction between text and table undermines reader trust in the reported event rates and is the most likely reviewer catch.
2. 2.
   HIGHreporting

   Correct the planned sample size inconsistency: the Methods state 1,424 patients; the Discussion states 1,428. Unify to the correct number (confirm from the protocol/statistical analysis plan) and ensure all instances match.

   A simple typographical inconsistency in the same manuscript suggests carelessness and invites questions about whether other numbers have been proofread.
3. 3.
   HIGHdata code

   Add a code availability statement in the Data availability section (or a separate 'Code availability' section) specifying that the analysis scripts (SAS code) are available upon request or deposited in a repository (e.g., Zenodo, GitHub) with a DOI or link.

   No code sharing is currently mentioned; this is the primary deficiency in data_code_availability and an increasingly standard expectation for clinical trial reports.
4. 4.
   MEDIUMstatistics

   In the Methods (Statistical analysis), add a brief statement verifying that the proportional hazards assumption for the interval-censored data model was assessed (e.g., by testing Schoenfeld residuals or a time-by-covariate interaction), even if the test was non-significant.

   Assumptions verification is not reported; adding this strengthens the statistical transparency and preempts reviewer queries.
5. 5.
   MEDIUMreporting

   In the Methods (Trial design), add a sentence stating that the DSMB and interim analysis were blinded, or if not, describe the unblinding procedure for the futility analysis.

   One reviewer noted that DSMB blinding is implicit but not explicitly described; a single sentence adds clarity and addresses a potential concern.
6. 6.
   MEDIUMreporting

   In the Methods or Discussion, provide a brief justification for the 2-point MoCA threshold for cognitive decline (e.g., citing the reliable change index or a prior validation study).

   The Discussion mentions that a 2-point change is a limitation, but placing the justification or citation in the Methods strengthens the a priori definition.
7. 7.
   MEDIUMreporting

   In the Methods (Statistical analysis), explicitly state that no outliers were excluded from the primary intention-to-treat analysis; if any sensitivity analyses excluded outliers, describe the criteria.

   Outlier handling is currently not reported; even if no outliers were excluded, stating this explicitly closes a checklist gap.
8. 8.
   MEDIUMreporting

   In the Abstract, rephrase 'patients with prior AF' to 'patients with AF' for clarity, since all enrolled participants had AF at baseline.

   Minor wording issue flagged by copyedit; 'prior AF' could confuse readers into thinking the AF had resolved.
9. 9.
   MEDIUMcopyedit

   In the Discussion (paragraph 5), correct the subject-verb agreement: change 'induces' to 'induce' to agree with the plural subject 'contractions' ('The irregular cardiac contractions characteristic of AF induce beat-to-beat variability').

   Grammatical error flagged by copyedit; a minor but visible fix.
10. 10.
    MEDIUMreporting

    In the Methods (Statistical analysis), rephrase the sentence about right-censored outcomes to explicitly state they were analyzed using log-rank tests and proportional hazards models stratified by study phase, to avoid ambiguity flagged by copyedit.

    Minor clarity improvement to ensure the analysis for each outcome type is unambiguously described.
11. 11.
    LOWreporting

    In Table 1 footnote, add a note that MoCA and MMSE scores are reported as means ± SD, in addition to the existing note for other continuous variables.

    Minor consistency improvement flagged by copyedit; ensures all mean values in the table are clearly labeled.
12. 12.
    LOWreporting

    If possible, deposit the deidentified aggregate data or summary statistics (e.g., baseline demographics by group, event counts per visit) in a public repository (e.g., Figshare, ClinicalTrials.gov results) to complement the controlled-access mechanism at SERIANT.

    Although the controlled-access route is adequate, a public aggregate dataset would increase transparency and reduce barriers for meta-analyses.